Syneron has agreed to acquire substantially all the assets of TransPharma Medical, a specialty pharmaceutical company focused on the development and commercialisation of drug products using an active transdermal drug-delivery technology. Under terms of the agreement, Syneron will acquire these assets, including its patent portfolio, for approximately US$3.6 million in cash. The acquisition is subject to customary closing conditions.
TransPharma has developed a transdermal drug-delivery technology based on RF-MicroChannels that creates microscopic channels across the skin. Its first product, the Viador system, is a hand-held device with an RF-needle array. It is CE mark approved for use in transdermal delivery of biologic drug-products via a system-specific skin patch. In the area of aesthetics, the Viador system has been shown to stimulate skin rejuvenation and increase penetration of cosmetic compounds and other pharmaceutical active ingredients to targeted layers of skin. The system is expected to provide a commercial opportunity within the professional and home-use aesthetic device markets.